Blueprint MedicinesBPMC
Market Cap: $5.41B
About: Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates includes AYVAKIT for the treatment of systemic mastocytosis, BLU-808 a potential treatment for mast cell disorders, including chronic urticaria, sleep disruption and other related diseases. It also has other drugs in its pipeline such as BLU-956, BLU-222 for treatment of breast cancer.
Employees: 655
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
167% more funds holding in top 10
Funds holding in top 10: 3 [Q1] → 8 (+5) [Q2]
105% more call options, than puts
Call options by funds: $287M | Put options by funds: $140M
96% more first-time investments, than exits
New positions opened: 51 | Existing positions closed: 26
14% more repeat investments, than reductions
Existing positions increased: 113 | Existing positions reduced: 99
14% more capital invested
Capital invested by funds: $6.27B [Q1] → $7.13B (+$856M) [Q2]
9% more funds holding
Funds holding: 276 [Q1] → 301 (+25) [Q2]
2.41% less ownership
Funds ownership: 108.05% [Q1] → 105.63% (-2.41%) [Q2]
Research analyst outlook
8 Wall Street Analysts provided 1 year price targets over the past 3 months
8 analyst ratings
Needham Ami Fadia 55% 1-year accuracy 70 / 128 met price target | 54%upside $133 | Buy Maintained | 5 Aug 2024 |
Guggenheim Michael Schmitz 33% 1-year accuracy 1 / 3 met price target | 60%upside $138 | Buy Maintained | 2 Aug 2024 |
Baird Joel Beatty 51% 1-year accuracy 18 / 35 met price target | 47%upside $127 | Outperform Maintained | 2 Aug 2024 |
Needham Ami Fadia 55% 1-year accuracy 70 / 128 met price target | 50%upside $130 | Buy Reiterated | 1 Aug 2024 |
Barclays Peter Lawson 29% 1-year accuracy 8 / 28 met price target | 21%upside $105 | Equal-Weight Maintained | 29 Jul 2024 |
Financial journalist opinion
Based on 33 articles about BPMC published over the past 30 days